HIV treatment breakthrough: monthly shots may replace daily pills

NCT ID NCT02938520

Ongoing Disease control Sponsor: ViiV Healthcare Source: ClinicalTrials.gov ↗

First seen Dec 31, 2025 · Last updated May 12, 2026 · Updated 22 times

Summary

This study tested whether adults with HIV whose virus is already suppressed can switch from taking daily pills to getting a monthly injection of two long-acting drugs (cabotegravir and rilpivirine). Over 600 participants were enrolled. The goal was to see if the shots keep the virus under control just as well as the daily pill regimen over 48 weeks. This approach offers a more convenient option for managing HIV long-term.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Long Beach, California, 90813, United States
GSK Investigational Site

Los Angeles, California, 90019, United States
GSK Investigational Site

Los Angeles, California, 90027, United States
GSK Investigational Site

Augusta, Georgia, 30912-3130, United States
GSK Investigational Site

Macon, Georgia, 31201, United States
GSK Investigational Site

Austin, Texas, 78705, United States
GSK Investigational Site

Bellaire, Texas, 77401, United States
GSK Investigational Site

Dallas, Texas, 75246, United States
GSK Investigational Site

Fort Worth, Texas, 76104, United States
GSK Investigational Site

Aichi, 460-0001, Japan
GSK Investigational Site

Osaka, 540-0006, Japan
GSK Investigational Site

Tokyo, 162-8655, Japan
GSK Investigational Site

Kazan', 420061, Russia
GSK Investigational Site

Kemerovo, 650056, Russia
GSK Investigational Site

Krasnodar, 350015, Russia
GSK Investigational Site

Lipetsk, 398043, Russia
GSK Investigational Site

Moscow, 115035, Russia
GSK Investigational Site

Oryol, 302040, Russia
GSK Investigational Site

Saint Petersburg, 190020, Russia
GSK Investigational Site

Saint Petersburg, 193167, Russia
GSK Investigational Site

Saint Petersburg, 196645, Russia
GSK Investigational Site

Saratov, 410009, Russia
GSK Investigational Site

Smolensk, 214006, Russia
GSK Investigational Site

Toliyatti, 445846, Russia
GSK Investigational Site

Yekaterinburg, 620102, Russia
GSK Investigational Site

Bloemfontein, 9301, South Africa
GSK Investigational Site

Cape Town, 7925, South Africa
GSK Investigational Site

Durban, 4052, South Africa
GSK Investigational Site

Durban, 4091, South Africa
GSK Investigational Site

Johannesburg, 2113, South Africa
GSK Investigational Site

Middelburg, 1055, South Africa
GSK Investigational Site

Pretoria, 0087, South Africa
GSK Investigational Site

Ferrol, 15405, Spain
GSK Investigational Site

Granada, 18016, Spain
GSK Investigational Site

La Laguna Santa Cruz, 38320, Spain
GSK Investigational Site

Madrid, 28041, Spain
GSK Investigational Site

Madrid, 28046, Spain
GSK Investigational Site

Murcia, 30003, Spain
GSK Investigational Site

San SebastiAn de Los Rey, 28702, Spain
GSK Investigational Site

Santa Cruz de Tenerife, 38010, Spain
GSK Investigational Site

Santander, 39008, Spain
GSK Investigational Site

Birmingham, B9 5SS, United Kingdom
GSK Investigational Site

Leeds Yorkshire, LS1 3EX, United Kingdom
GSK Investigational Site

London, E1 1BB, United Kingdom

Conditions

Explore the condition pages connected to this study.

HIV INFECTIONS